Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia
Elżbieta Radzikowska1, Adriana Roży2, Paulina Jagus2
1Third Department of Lung Disease, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland.
Background:
Inflammatory cytokines are involved in the development of cryptogenic organizing pneumonia (COP). It has been shown that macrolides inhibit cytokine production in the alveolar macrophages of COP patients.
Objectives:
The aim of the study was to assess the concentrations of interleukin 1β (IL-1β), IL-6, IL-8 and transforming growth factor β (TGF-β) in serum and in bronchoalveolar lavage fluid (BAL-f) in COP patients treated with clarithromycin (CAM).
Material And Methods:
The study involved 26 patients (18 women and 8 men, mean age 56.46 ± 8.83 years) with biopsy-proven COP. After being treated with CAM, a complete recovery was achieved in 22 patients, while four patients did not respond to the treatment. The ELISA method was used to measure the serum and BAL-f concentrations of IL-1β, IL-6, IL-8 and TGF-β.
Results:
Before treatment, the serum IL-1β1, IL-6, IL-8 and TGF-β1 concentrations were similar in responders and non-responders. Significant decreases in serum concentrations of IL-6 (8.98 ± 13.26 pg/mL vs. 3.1 ± 6.95 pg/mL; p = 0.005), IL-8 (20.14 ± 25.72 pg/mL vs. 10.14 ± 6.8 pg/mL; p = 0.007) and TGF-β1 (37.89 ± 12.49 ng/mL vs. 26.49 ± 12.45 ng/mL; p = 0.001) were found after treatment, as well as a significant decrease in the BAL-f concentration of IL-6 (30.56 ± 56.78 pg/mL vs. 4.53 ± 5.84 pg/mL; p = 0.036). Clarithromycin treatment resulted in a significantly lower mean value of serum IL-6 responders than non-responders.
Conclusions:
In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-β, and of rations, and of the BAL-f concentration of IL-6.
Insights
Clarithromycin treatment reduced key inflammatory markers like IL-6, IL-8, and TGF-β in patients with cryptogenic organizing pneumonia (COP). This reduction in cytokines correlated with treatment response in COP patients.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Cryptogenic organizing pneumonia (COP) is linked to inflammatory cytokines.
- Macrolides, such as clarithromycin, are known to inhibit cytokine production in alveolar macrophages of COP patients.
Purpose of the Study:
- To evaluate serum and bronchoalveolar lavage fluid (BAL-f) concentrations of interleukin 1β (IL-1β), IL-6, IL-8, and transforming growth factor β (TGF-β) in COP patients.
- To assess the impact of clarithromycin (CAM) treatment on these cytokine levels.
Main Methods:
- The study included 26 patients with biopsy-proven COP.
- Cytokine levels were measured using the ELISA method before and after clarithromycin treatment.
- Patients were categorized into responders (22) and non-responders (4) based on treatment outcome.
Main Results:
- Significant decreases in serum IL-6, IL-8, and TGF-β1 were observed post-treatment.
- A significant reduction in bronchoalveolar lavage fluid (BAL-f) IL-6 concentration was also noted.
- Responders showed significantly lower serum IL-6 levels compared to non-responders after treatment.
Conclusions:
- Clarithromycin treatment in COP patients is associated with reduced serum concentrations of IL-6, IL-8, and TGF-β.
- Decreased BAL-f IL-6 concentration is also linked to treatment response.
- These findings suggest a role for clarithromycin in modulating inflammatory pathways in COP.
More Related Videos
06:29Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...